sulfur 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4260 7704-34-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sulfur
An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.
  • Molecular weight: 32.06
  • Formula: S
  • CLOGP:
  • LIPINSKI: None
  • HAC: 0
  • HDO: 0
  • TPSA:
  • ALOGS:
  • ROTB: 0

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 17, 1940 FDA POYTHRESS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 95.05 13.92 145 7131 310542 63171204
Broncholithiasis 72.56 13.92 14 7262 239 63481507
Lymph node calcification 68.76 13.92 14 7262 318 63481428
Bronchial wall thickening 47.79 13.92 14 7262 1485 63480261
Lower respiratory tract infection viral 40.23 13.92 11 7265 910 63480836
Lichen nitidus 38.35 13.92 7 7269 87 63481659
Exposure to toxic agent 29.84 13.92 14 7262 5573 63476173
Oesophagitis 28.38 13.92 19 7257 14989 63466757
Sexual abuse 21.39 13.92 5 7271 219 63481527
Soft tissue necrosis 21.01 13.92 6 7270 581 63481165
Vision blurred 17.60 13.92 35 7241 91889 63389857
Neuropathy peripheral 16.84 13.92 39 7237 113628 63368118
Death 16.84 13.92 86 7190 374295 63107451
Psoriasis 16.52 13.92 33 7243 86924 63394822
Aplastic anaemia 15.47 13.92 11 7265 9558 63472188
Dehydration 15.16 13.92 49 7227 173305 63308441
Obstructive airways disorder 15.05 13.92 15 7261 20684 63461062
Ovarian cyst 14.34 13.92 13 7263 15932 63465814

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Choroiditis 55.12 17.25 15 4057 1200 34951659
Endophthalmitis 46.82 17.25 17 4055 3491 34949368
Visual acuity reduced 34.03 17.25 22 4050 16127 34936732
Intraocular pressure increased 30.13 17.25 14 4058 5369 34947490
Eye pain 22.76 17.25 16 4056 13446 34939413
Chondritis 22.68 17.25 5 4067 165 34952694
Post inflammatory pigmentation change 19.91 17.25 5 4067 292 34952567
Dysphagia 19.87 17.25 30 4042 62351 34890508
Completed suicide 19.16 17.25 38 4034 98130 34854729
Exposure to toxic agent 18.85 17.25 9 4063 3666 34949193
Radiation oesophagitis 17.95 17.25 5 4067 436 34952423

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 87.10 13.62 134 8692 298782 79436780
Broncholithiasis 67.44 13.62 13 8813 229 79735333
Lymph node calcification 60.45 13.62 13 8813 402 79735160
Exposure to toxic agent 49.85 13.62 23 8803 9135 79726427
Choroiditis 49.41 13.62 14 8812 1367 79734195
Lichen nitidus 38.37 13.62 7 8819 90 79735472
Bronchial wall thickening 36.64 13.62 13 8813 2628 79732934
Endophthalmitis 34.53 13.62 16 8810 6412 79729150
Lower respiratory tract infection viral 33.19 13.62 10 8816 1210 79734352
Soft tissue necrosis 31.49 13.62 9 8817 906 79734656
Visual acuity reduced 31.26 13.62 26 8800 29443 79706119
Death 30.76 13.62 134 8692 566380 79169182
Completed suicide 30.46 13.62 77 8749 245690 79489872
Toxicity to various agents 21.54 13.62 98 8728 421442 79314120
Intraocular pressure increased 21.13 13.62 13 8813 9192 79726370
Psoriasis 19.10 13.62 35 8791 89552 79646010
Vision blurred 18.46 13.62 38 8788 105860 79629702
Post inflammatory pigmentation change 17.86 13.62 5 8821 467 79735095
Chondritis 17.58 13.62 4 8822 161 79735401
Eye pain 15.58 13.62 20 8806 37558 79698004
Oesophagitis 15.24 13.62 16 8810 24273 79711289
Pain of skin 13.67 13.62 12 8814 14601 79720961

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D10AB02 DERMATOLOGICALS
ANTI-ACNE PREPARATIONS
ANTI-ACNE PREPARATIONS FOR TOPICAL USE
Preparations containing sulfur
CHEBI has role CHEBI:33286 agricultural chemicals
CHEBI has role CHEBI:35718 antifungal agents
CHEBI has role CHEBI:75772 S. cerevisiae metabolites
CHEBI has role CHEBI:33937 macronutrients

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Greasy skin indication 42273000
Seborrheic dermatitis indication 50563003 DOID:8741
Acne vulgaris indication 88616000
Pityriasis simplex indication 200767005
Acute necrotizing ulcerative gingivitis indication 399050001
Acneiform eruption indication 402644006
Aphthous ulcer of mouth indication 426965005 DOID:9663
Rosacea off-label use 398909004 DOID:8881
Itching of skin off-label use 418363000
Infection of skin AND/OR subcutaneous tissue contraindication 19824006
Conduction disorder of the heart contraindication 44808001
Diabetes mellitus contraindication 73211009 DOID:9351
Decreased respiratory function contraindication 80954004
Kidney disease contraindication 90708001 DOID:557
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Open wound contraindication 125643001
Seizure disorder contraindication 128613002
Condyloma acuminatum contraindication 240542006 DOID:11168
Telangiectasia disorder contraindication 247479008
Eruption of skin contraindication 271807003 DOID:0050486
Skin irritation contraindication 367466007
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Atrophoderma contraindication 399979006
Erythroderma contraindication 399992009
Peripheral vascular disease contraindication 400047006
Blister contraindication 417237009
Denuded skin contraindication 418242004
Inflammatory dermatosis contraindication 703938007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Carbonic anhydrase 2 Enzyme Ki 4.40 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 6.22 CHEMBL

External reference:

IDSource
4018870 VUID
N0000147169 NUI
D00024 KEGG_DRUG
4018870 VANDF
C0038774 UMLSCUI
CHEBI:26833 CHEBI
CHEMBL2105487 ChEMBL_ID
D013455 MESH_DESCRIPTOR_UI
70FD1KFU70 UNII
5362487 PUBCHEM_CID
10223 RXNORM
5415 MMSL
5534 MMSL
NOCODE MMSL
002558 NDDF
002997 NDDF
332304007 SNOMEDCT_US
43735007 SNOMEDCT_US
10544-50-0 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Avar-e Green HUMAN PRESCRIPTION DRUG LABEL 2 0178-0460 CREAM 50 mg TOPICAL unapproved drug other 13 sections
Avar-e LS HUMAN PRESCRIPTION DRUG LABEL 2 0178-0465 CREAM 20 mg TOPICAL unapproved drug other 12 sections
Avar-e HUMAN PRESCRIPTION DRUG LABEL 2 0178-0470 CREAM 50 mg TOPICAL unapproved drug other 12 sections
AVAR LS HUMAN PRESCRIPTION DRUG LABEL 2 0178-0475 EMULSION 20 mg TOPICAL unapproved drug other 12 sections
AVAR LS HUMAN PRESCRIPTION DRUG LABEL 2 0178-0475 EMULSION 20 mg TOPICAL unapproved drug other 12 sections
AVAR HUMAN PRESCRIPTION DRUG LABEL 2 0178-0480 EMULSION 50 mg TOPICAL unapproved drug other 12 sections
AVAR HUMAN PRESCRIPTION DRUG LABEL 2 0178-0480 EMULSION 50 mg TOPICAL unapproved drug other 12 sections
Adult Acnomel Tinted HUMAN OTC DRUG LABEL 2 0295-9116 CREAM 8 g TOPICAL OTC monograph final 12 sections
Sulfo lo HUMAN OTC DRUG LABEL 1 0316-0118 SOAP 30 mg TOPICAL OTC monograph final 8 sections
Sulfo lo HUMAN OTC DRUG LABEL 1 0316-0118 SOAP 30 mg TOPICAL OTC monograph final 8 sections
Tinted Acne Treatment HUMAN OTC DRUG LABEL 2 0363-7783 CREAM 8 g TOPICAL OTC monograph final 7 sections
Sebex Antidandruff, anti-seborrheic dermatitis, anti-psoriasis HUMAN OTC DRUG LABEL 2 0536-1962 SHAMPOO 20 mg TOPICAL OTC MONOGRAPH FINAL 14 sections
Sulfur HUMAN OTC DRUG LABEL 1 10095-007 OINTMENT 10 g TOPICAL OTC monograph final 8 sections
REZAMID HUMAN OTC DRUG LABEL 2 11086-022 LOTION 5 g TOPICAL OTC monograph final 11 sections
REZAMID HUMAN OTC DRUG LABEL 2 11086-022 LOTION 5 g TOPICAL OTC monograph final 11 sections
LIQUIMAT ACNE TREATMENT AND COVER-UP HUMAN OTC DRUG LABEL 1 11086-028 LIQUID 3 g TOPICAL OTC monograph final 11 sections
LIQUIMAT ACNE TREATMENT AND COVER-UP HUMAN OTC DRUG LABEL 1 11086-028 LIQUID 3 g TOPICAL OTC monograph final 11 sections
Kate Summerville EradiKate HUMAN OTC DRUG LABEL 1 11090-263 CREAM 3 g TOPICAL OTC monograph final 11 sections
Sulfo lo HUMAN OTC DRUG LABEL 1 11118-0007 SOAP 30 mg TOPICAL OTC monograph final 9 sections
Sulfo lo HUMAN OTC DRUG LABEL 1 11118-0007 SOAP 30 mg TOPICAL OTC monograph final 9 sections
Sulfur HUMAN OTC DRUG LABEL 1 11118-0009 SOAP 5 g TOPICAL OTC monograph final 9 sections
Sulfur HUMAN OTC DRUG LABEL 1 11118-0009 SOAP 5 g TOPICAL OTC monograph final 9 sections
Madina Acne HUMAN OTC DRUG LABEL 1 11118-0073 SOAP 3 g TOPICAL OTC monograph final 9 sections
Madina Acne HUMAN OTC DRUG LABEL 1 11118-0073 SOAP 3 g TOPICAL OTC monograph final 9 sections
Madina Acne HUMAN OTC DRUG LABEL 1 11118-0073 SOAP 3 g TOPICAL OTC monograph final 9 sections
THYLOX HUMAN OTC DRUG LABEL 1 11118-1002 SOAP 3 g TOPICAL OTC monograph final 9 sections
THYLOX HUMAN OTC DRUG LABEL 1 11118-1002 SOAP 3 g TOPICAL OTC monograph final 9 sections
THYLOX HUMAN OTC DRUG LABEL 1 11118-1002 SOAP 3 g TOPICAL OTC monograph final 9 sections
GRANDPAS THYLOX ACNE TREATMENT WITH SULFUR HUMAN OTC DRUG LABEL 1 11118-1006 SOAP 3 g TOPICAL OTC monograph final 9 sections
GRANDPAS THYLOX ACNE TREATMENT WITH SULFUR HUMAN OTC DRUG LABEL 1 11118-1006 SOAP 3 g TOPICAL OTC monograph final 9 sections